How confident are you in your country’s healthcare system? It’s the central issue for this month’s cover feature, which focuses on a global study of healthcare perceptions and offers up useful insights into how people think and feel when faced with healthcare decisions.
We also look at the global scourge that is the problem of counterfeit medicines and hear what the industry is doing to help tackle the problem.
And there’s a preview of the options open to the EMA when it issues its forthcoming drug shortage report and a look at the measures already taken by the likes of France and Portugal.
Last month we looked at what the Brexit vote to leave the European Union will mean for the European pharmaceutical industry. With clarity on the issue still in rather short supply, this month we concentrate on the implications of Brexit for the UK biopharma industry.
Meanwhile, we look at business models, of which Professor Brian D Smith says 26 are theoretically on offer in pharma. Charting a successful course is fraught with hidden and not-so-hidden dangers, but – as Prof Smith explains – the complications can be boiled down to their fundamentals, and a four-stage process.
Finally, we put the spotlight on managing the cultural changes that occur when companies merge and acquire, from retaining your core values to preventing ‘brain drain’ and engaging with your workforce.
Also, with this issue you’ll find our latest European Market Access supplement. In it we look at the direction of travel in France and Germany and introduce the UK’s new-look Cancer Drugs Fund.
View PME September 2016 online
Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
PME is also available to download as an app for iPhone and iPad
